CVS/pharmacy to Remove OTC Infant Cough & Cold Products from Its Stores as Part of CHPA's Voluntary Withdrawal
Over-the-counter children's cough and cold medicine is safe and effectivewhen used as directed. CHPA has announced the voluntary withdrawal of oralOTC infant cough and cold products due to rare instances of misuse leading tooverdose, particularly involving infants under the age of two.
Effective immediately, CVS/pharmacy will remove from its stores allproducts subject to this voluntary withdrawal, as well as any CVS/pharmacyBrand equivalents. A block is being placed in our point-of-sale system toprevent sales of these items and all affected product is being removed fromour store shelves. Customers who purchased any of these products atCVS/pharmacy may return them for a full refund.
Customers should discuss with their CVS pharmacist or their children'spediatrician alternative methods that are available for treating cough andcold symptoms in children under the age of two.
"The health and safety of our customers and their children is our highestpriority," said Mike Bloom, Senior Vice President of Merchandising atCVS/pharmacy. "We support this voluntary action because CHPA is dedicated toensuring the safety of healthcare products on the market and their members aresome of our most trusted suppliers."
The voluntary product withdrawal does not affect infant and children'spain relievers, single-ingredient analgesics and nasal spray, drops or rubsfor infants, or cough and cold medicines for children ages two and above.
For a complete list of products being voluntarily withdrawn or for moreinformation about the withdrawal, please visit http://www.otcsafety.org .
CVS/pharmacy, the retail division of CVS Caremark Corporation, isAmerica's largest retail pharmacy with approximately 6,200 retail locations.CVS/pharmacy is committed to serving the healthcare needs of all customers bybeing the easiest pharmacy for customers to use, both in its stores and onlineat CVS.com. General information about CVS/pharmacy and CVS Caremark isavailable at http://www.cvs.com/pressroom, as well as http://investor.cvs.com.
You May Also Like